The Metabo category covers the incretin-pathway compounds that have reshaped metabolic research over the past five years. Single- and dual-receptor agonists — including tirzepatide and semaglutide — sit alongside amylin analogs and adjacent metabolic peptides. Every lot ships with a third-party COA documenting purity, identity, and endotoxin status to ISO-17025 standards.